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“Approximation of the truth is all that we have”
Alan Chalmers

Abstract
Despite extensive research during the last decades, coronary artery disease (CAD)
remains the number one cause of death, responsible for near 50% of global mortal-
ity. A main reason for this is that CAD has a complex inheritance and etiology
that unlike rare single gene disorders cannot fully be understood from studies of of
genes one-by-one.In parallel, studies that simultaneously assess multiple, function-
ally associated genes are warranted. For this reason we undertook the Stockholm
Atherosclerosis Gene Expression (STAGE) study that besides careful clinical charac-
terization and genome-wide DNA genotyping also assessed the global gene expression
profiles from seven CAD-relevant vascular and metabolic tissues.
In paper I, we used STAGE to develop a bioinformatics tool for efficient eQTL
mapping called kruX based on Kruskal-Wallis statistics test. kruX excels in de-
tecting a higher proportion of nonlinear expression quantitative expression traits
loci (eQTLs) compared to other established methods. This tool was developed for
Python, MATLAB, and R and is available online. In paper II, we applied kruX
to detect eQTLs across the seven tissues in STAGE and assessed their tissue speci-
ficity. A tool for analyzing inherited risk enrichment was also developed assessing
CAD association (i.e., risk enrichment) of STAGE eQTLs according to genome-wide
association studies (GWAS) of CAD. We found that eQTLs active across multiple
vascular and metabolic tissues are more enriched in inherited risk for CAD than
tissue-specific eQTLs. In paper III, we integrate the analysis of STAGE data with
data from GWAS of CAD to identify 30 regulatory-gene networks causal for CAD.
In paper IV, we again used kruX to investigate STAGE eQTLs for three established
candidate genes in CAD and atherosclerosis (ALOX5, ALOX5AP, and LTA4H). In
addition, we used the Athero-Express dataset of genotype and atherosclerotic carotid
plaque characteristics to further elucidate the role of these genes in atherosclerosis
development.
In sum, in this thesis report we show that by integrating GWAS with genet-
ics of gene expression studies like STAGE, we can advance our understanding from
the perspective of multiple genes and gene variants acting in conjunction to cause
CAD in the form of regulatory gene networks. This is done through developing new
bioinformatics tools and applying them to disease-specific, genetics of global gene
expression studies like STAGE. These tools are necessary to go beyond our current
limited single-gene understanding of complex traits, like CAD.
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1 Background
Over the last few decades, socioeconomic changes improved standards of living
(health, hygiene, and nutritional habits), and medical advances have led to de-
clines in mortality rates from infectious diseases and nutritional deficiencies and a
shift toward degenerative diseases, such as cardiovascular disease (CVD, a disease
of heart and peripheral vessels) and diabetes [1, 2, 3]. This so-called epidemiological
transition reflects the modernization of societies, mostly in middle-income and devel-
oped countries [2]. The increase in CVD-related incidents suggests that the effects
of environmental and behavioral factors have been underestimated. According to
the World Health Organization (WHO), CVD is the predominant cause of mortality
worldwide, accounting for approximately 30% of deaths (17.3 million people in 2013)
to a different extent in men and women [4]. Approximately 40% of the CVD-related
mortality was from coronary artery disease (CAD) and stroke [4].
1.1 Coronary Artery Disease: a Disease of Arteries of
the Heart
Coronary artery disease (CAD) is caused by atherosclerosis of arteries in the heart.
Also known as atherosclerotic CVD, CAD is a progressive lifelong inflammatory
disease [5, 6, 7], whose course can be influenced by metabolic disturbances in the
body [8]. This disease mainly affects large and intermediate-sized arteries. It is
characterized by gradual accumulation of inflammatory cells (leukocytes), a growing
lipid core, and migration of smooth muscle cells (SMC) into the arterial wall [5, 6].
Eventually, fatty streaks develop and mature into atherosclerotic plaques [5, 6].
1.1.1 Arteries and their Structure
Arteries are the vessels that carry blood from the heart to other organs in the body.
Large arteries have three distinct layers: intima, media, and adventitia. Intima, the
closest layer to the lumen, is composed of a single layer of endothelial cells (EC)
and a basal membrane that attaches EC to connective tissues. The EC layer is a
selectively permeable barrier for materials to pass through. It also provides strength
and flexibility to the intima. Media, the middle and generally thickest layer, is
mainly composed of SMC and some connective tissue. SMC are bound to the other
two layers by collagen fibers. The adventitia, the outermost layer, can be thicker
than media in large arteries and is mainly composed of collagen fibers, connective
tissue, and perivascular nerves.
1.1.2 Molecular Events of Atherosclerosis
Two main physiological functions of the endothelial monolayer are to provide a non-
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adhesive barrier for blood to flow smoothly and to modulate constriction of SMC to
dilate or constrict the vascular wall based on demand [5]. Any change or damage
to the endothelial layer that inhibits or alters its function is referred to as endothe-
lial dysfunction (ED). ED can be caused by systemic factors, such as increases in
blood cholesterol levels (hypercholesterolemia) or blood pressure (hypertension), or
local factors, such as blood flow dynamics and inflammation [5]. ED can alter en-
dothelial permeability (due to shear blood flow stress) and increase the expression
of adhesion molecules [5], setting the stage for a key initiating event in the devel-
opment of atherosclerotic plaques-infiltration of low-density lipoproteins (LDL) into
the subendothelial layer. The rates of infiltration and retention are accelerated by
hypercholesterolemia and other systemic changes. Within the subendothelial layer,
retained LDL are modified into oxidized LDL (oxLDL) and activate EC to express
adhesion molecules. Circulating inflammatory cells (mainly monocytes) attach to
these molecules and migrate to the subendothelium, where the monocytes differen-
tiate into macrophages, which take up oxLDL and transform into foam-like cells,
which aggregate into fatty streaks - the starting point of atherosclerotic plaque.
Foam cells at the heart of the plaque may die [9] and burst in the ever-growing core.
During this initial inflammatory response and foam-cell formation, SMC migrate
from the media. A SMC-derived extracellular matrix forms and encapsulates the
growing core. Eventually, a fibrous cap forms. Migrated inflammatory cells also
secrete cell growth and proliferation factors and inflammatory cytokines (signaling
proteins) that elicit an additional inflammatory response and cause SMC prolifera-
tion. In complex plaques, the growing core may become calcified [5].
1.1.3 Clinical Manifestation of Atherosclerosis
Atherosclerotic plaques can become so large that they bulge toward the vessel lumen.
The plaques have two general forms (or a mixture of both): stenotic and nonstenotic
[10]. Stenosis refers to narrowing of lumen, which can reduce or block blood flow.
Stenotic plaques have smaller lipid core and a thick fibrous cap, whereas nonstenotic
plaques have larger lipid core and a thin fibrous cap. Unlike stenotic plaques, non-
stenotic plaques are vulnerable to rupture at the shoulder region from causes in-
cluding physical disruption, extracellular matrix degradation by macrophages, and
reduction of matrix formation by SMCs. When the plaque ruptures, a blood clot
(thrombus) forms at the site of the rupture and can block blood flow in the lu-
men (thrombosis). The thrombus can break loose from the vessel wall, becoming
an embolus that travels with the circulation. Thrombosis and emboli can lead to
complications such as myocardial infarction and stroke.
1.1.4 CAD is a Multifactorial Disease
CAD is a common disease whose development is affected by many risk factors. For
that reason it is referred to as common complex disease (CCD). The risk factors
range from isolated local molecular events at the atherosclerotic plaque site or distal
molecular events in metabolic tissues such as the liver. These risk factors can be
either modifiable or nonmodifiable and can have both direct effects (casual) and
indirect effects on disease development. The modifiable risk factors include obesity,
diabetes, dyslipidemia, hypertension, inflammation, smoking and tobacco consump-
tion, high-fat diet, and sedentary lifestyle. Examples of nonmodifiable risk factors
are age, gender, and family history. Both group of risk factors are governed by
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genetics (e.g., family history) and its interaction with lifestyle and environmental
variables (e.g., smoking and high-fat diet). Some of the major risk factors are briefly
discussed below.
• Family history and inheritance: The Framingham Heart Study showed that
family history is a risk factor for CAD [11], that there is an inheritance pattern
for CAD [12, 13], the effect of mutation in single gene leading to atherosclerosis
and CAD [13, 14] and that it aggregates in families, reflecting the heritability
of CAD [15, 11].
• Obesity and type 2 diabetes: Insulin resistance is the link between obesity and
CAD [16]. Insulin resistance has been linked to waist circumference (WC;
i.e., abdominal obesity) [16], waist-to-hip ratio (WHR) [17], and body mass
index (BMI). This implies that there is a direct link between obesity and
CAD development risk. Therefore, body fat distribution (visceral fat and
subcutaneous fat) can be predictors of CAD risk [16]. Thus, the importance
of studying molecular events within visceral fat and subcutaneous fat. Also,
insulin resistence manifests itself in skeletal muscle and fat tissues, two insulin
senstive tissues, as impairment in glucose transport [18].
• Dyslipidemia: The liver has an important role in lipid metabolism, which is
associated with risk for CAD. High levels of LDL, low levels of high-density
lipoproteins (HDL), and high levels of triglyceride (TG) are strongly associated
with increased CAD risk [19].
• Hypertension: Hypertension is also associated with CAD risk, and elevated
systolic and diastolic blood pressure, each have been linked to CAD mortality
[18]. Insulin resistence is also link to the blood flow by impairing vascular
relaxation in skeletal muscle and fat tissues [18]. An important effect of hy-
pertension is mechanical pressure and turbulent blood flow that stress the
arterial wall, especially at branching points, which can contribute to disease
development.
• Inflammation: Inflammation - the interaction between metabolic factors and
immune mechanisms - is a key risk factor for CAD that contributes to the
initiation and progression of atherosclerosis [7, 20, 21].
• Smoking: Smoking is responsible for least 10% of all CVD incidents [4].
Cigarette smoking in particular contributes to disease risk by increasing the
risk of type 2 diabetes - itself is a major risk factor for CAD. Oxidants are
thought to be the main driver of CAD risk from smoking, as almost all pub-
lished research articles found no direct effect of nicotine and tobacco consump-
tion (including smokeless tobacco) on CAD risk [22].
• Sedentary lifestyle: Physical inactivity is a major contributor to risk for CAD
and other chronic diseases [23], including obesity, hypertension, diabetes, and
metabolic syndromes, which also increase risk for CAD [24]. Among individu-
als with low physical activity, CAD risk is 2.7-fold higher than in individuals
with higher physical activity [24].
3
1 Background
1.2 Genetics of Rare and Common Diseases
1.2.1 The Genome
There are 23 pairs of chromosomes in the humane genome: 22 pairs of autosomal
chromosomes and one pair of sex chromosomes. The building blocks of DNA (de-
oxyribonucleic acid) are pairs of four bases (A, C, T, and G ) that form pairs A-T
and C-G. Genes are stretches of bases in the DNA that are transcribed into messen-
ger ribonucleic acid (mRNA) that give rise to proteins (i.e. central dogma of biology
DNA→mRNA→proteins - which states that DNA determines how and which pro-
teins are produced inside every cell, first through transcription then through trans-
lation into proteins). The number of protein-coding genes is estimated to be around
20,000. The protein-coding genes are crucial being the building blocks of all cells
and tissue functions. They only form about 1.5% of the DNA; the remaining 98.5%
of so called non-coding DNA is poorly understood but increasingly believed to have
important gene regulatory roles.
1.2.2 Genetic Variation
Human chromosomes are paired, with one chromosome inherited from each par-
ent. Any two individuals have 99.9% similar sequence in their genome [25]. The
0.1% difference constitutes the genetic variation. Variable part of the genome cov-
ers an estimated 10-30 million bps that is found in at least 1% of the population.
Genetic variations arise from spontaneous mutations or recombination that remain
conserved through evolution [26]. A location in the DNA with genetic variance that
is associated with disease or other types phenotypes is called a genetic locus. Ge-
netic variance in these loci is mainly from two types of DNA variants; copy number
variations (CNVs) and single nucleotide polymorphisms (SNPs). CNVs are DNA
sequences that appear at a variable number of copies. SNPs, the most common type
of genetic variation, are single substitute, insertion, or deletion of base pairs (bp).
On average there is one SNP in every 300 base pair. Each SNP has two alleles.
Individuals with the two identical alleles are called homozygous, and those with two
different alleles are called heterozygous.
Nearby SNPs tend to covary with each other. A set of SNPs that co-vary is
called a haplotype block [27]. Two SNPs are said to be in linkage disequilibrium
(LD) when their alleles are highly correlated in the population. A high LD corre-
sponds to a statistical correlation, r2 ≥ 0.8 or r2 ≥ 0.9. A typical LD-block spans
60–200 kbp [27, 28, 29].
1.2.3 Mendelian Diseases
Mendelian diseases are due solely to genetic causes (i.e., disease-causing variants)
and follow a Mendelian inheritance pattern - one that is controlled by a single or few
locus that is transmitted from parents to offspring. There are two types of Mendelian
inheritance patterns: (1) autosomal dominant (or sex-linked dominant) inheritance,
which requires only one copy of a defective allele or a set of alleles occuring in every
generation (e.g., Huntingtons disease, or fragile X syndrome) [30] The second one (2)
is autosomal recessive (or sex-linked recessive) inheritance, which requires two copies
of the same defective allele(s) (e.g., cystic fibrosis) or if on the X chromosome, one
copy of the defective allele(s) for males or two copies of defective allele(s) in females
4
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(e.g., hemophilia A) [30]. Mendelian diseases can range from rare diseases caused
by a set of variants in a specific locus to diseases caused by a single defective gene
[31, 32, 33] to multigenic diseases caused by many genes [34]. An important aspect
of Mendelian diseases is that the disease-causing variants have low frequency but
high penetrance and a large effect size [35].
1.2.4 Common Complex Diseases
Common complex diseases (CCDs) are governed by inheritance patterns-heritable
traits with a complex genetic architecture. The disease-causing variants found so
far for CCDs, have, unlike Mendelian disorders, a higher frequency (minor allele
frequency [MAF] ≥ 5%), low penetrance, and a small effect size. Disease risk is in
contrast to Mendelian diseases thought to be caused by the combination of many
genes also interacting with environmental factors. An important hypothesis for stud-
ies of common diseases is the common disease, common variant hypothesis, which
assumed that common genetic variants (MAF ≥ 1–5%) are the main contributors
to genetic susceptibility of common diseases. However, recently by GWAS identi-
fied common variants explain about 10% of disease heritability, and the majority
of heritability in the population is unaccounted for [35, 36, 37, 38]. Some of the
approximately 90% missing heritability will be found by rare variants causing CCDs
[35]. Other reasons might be so called epistatic effects, which roughly means that
genetic variants linked to a given CCD act in conjunction to explain more of the
genetic variance of the disease than the sum of their individual effects [39].
1.2.5 Design for Genetic Studies of Rare versus Common Complex
Diseases
There are two main approaches for studying rare and common diseases:
a) Genetic linkage studies: In Genetic linkage studies identified genomic re-
gions or gene(s) are linked based on patterns of inheritance in families [40].
This approach has been dominant for rare diseases.
b) Genome-wide association studies: In Genome-wide association studies
(GWAS) SNP alleles are tested for association with a disease phenotype at
the population level with a case–control setup[41]. This approach is used for
genetic studies of CCDs. Two types of SNP-disease association can be inferred
from GWAS: direct and indirect [Figure 1]. In a direct association, the SNP is
the true causal variant for disease risk [41, 42]. In an indirect association, the
SNP is in LD with the true causal SNP [41, 42]. SNPs can be in noncoding
regions or protein-coding regions of the DNA. Most SNPs identified so far by
GWAS are in in none-coding region and thus, believed to effect gene expression
regulation rather than function of the gene.
A main issues with GWAS is the multiple testing problem. Typically, 2 million
SNPs are tested one-by-one resulting in that a p value of 2.5×10−8 (after Bon-
ferroni correction,) becomes the threshold to filter for genome-wide significant
associations. A strategy to meet the multiple testing problem is to combine
multiple GWAS datasets as a meta-analysis to increase power of the study.
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Figure 1: Direct and indirect association. If a genetic marker (orange) is in
LD with a disease-susceptible allele (red), and there is evidence of association
between the genetic marker and the disease phenotype, it is said that the disease-
susceptible allele is also associated with the disease phenotype. This is known
as “guilt by association” or indirect association.
1.2.6 Genetics of Gene Expression Studies
Systems genetics based on the use of genetics of gene expression studies (GGES) is
an increasingly appreciated solution to complement GWAS for better understanding
of CCD etiology. GGES introduces one or several intermediate phenotypes between
DNA and the phenotypes shortening the biological distance allowing for smaller
studies in the range of hundreds to a thousand individuals. We focused on gene and
RNA expression profiles, but future studies will also consider other intermediate
phenotypes, such as protein and metabolite expression [43]. RNA is a useful first
step in mapping expression quantitative trait loci (eQTLs) across the genome and
to decipher gene networks [44]. Detecting eQTLs is a powerful technique to assign
gene regulatory functions of DNA variants. The fact that gene or RNA expression is
an immediate consequence of DNA genotypes make these associations statistically
stronger than for those sought between DNA and phenotypes in GWAS - allowing to
detect eQTLs in smaller studies (i.e. smaller number of study subjects) than what
is needed in GWAS.
This section will start by describing quality control (QC) procedures for GGES
and by explaining how to map eQTLs. It will conclude by covering kruX and
MatrixeQTL, the two eQTL mapping methods we used in this thesis.
1.2.7 Quality Control for Genotype Data
Several measures must be taken into account to ensure that the data are of sufficient
quality to prevent false variation frequently related to technical noise from sample
handling rather than true biological or disease variation this is done during the
quality control (QC) procedure. Here are some QC steps we used in this thesis:
• Individual gender check: It is important to filter and QC for gender mis-
matches, as it can be a covariate in a study. This QC step can be done at
the genotype level, usually method by checking for SNPs on X chromosomes.
Since X chromosomes are typically genotyped for SNPs, all Y chromosome
SNPs will be missing. Thus males should have a homozygosity rate of 1 and
females should typically have a much lower homozygosity rate [45].
• Individual genotype call rate: A very high threshold for genotype call
rate can affect the data in two ways: loss of power from loss of individuals
being filtered out and informative missingness. The former can happen if
DNA sample quality is not high enough, which leads to most SNPs being
6
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improperly called. The latter is more complex and is a dilemma for genotype-
calling algorithms. These algorithms attempt, on the basis of signal intensity,
to assign a genotype with very high certainty or to guess a genotype with a low
certainty. The former may lead to “informative missingness”, where a genotype
might be correlated to its status of being missed (e.g. a rare genotype) [45].
A recommended 3–7% call rate threshold has been previsouly used [46].
• Individual relatedness: Generally speaking, related (or duplicate) individ-
uals can introduce false positive or false negative results (by affecting allele
frequencies). Two measures are used to address this problem: identity by
state (IBS) for duplicates and identity by descent (IBD) for relatedness be-
tween individuals. IBS shows how similar to each other two or sets of alleles
or portions of DNA in two individuals are; IBD shows how related these seg-
ments are in terms of sharing common ancestry [45, 47].First, the short and
long range of LD should be addressed to remove highly correlated SNPs. The
reason is that individual relatedness analysis achieves the best results by as-
suming that SNPs are not in LD with each other. Sometimes, the extended
LD regions are removed entirely [45]. The rest of the SNPs within short-range
LD regions should be LD-pruned. [45]. Second, the IBS and IBD scores should
be analyzed [48]. If two individuals have very high IBS score, close to 1, they
are most probably duplicates. And from genome-wide IBS data, we can derive
IBD. Duplicates or monozygotic twins have an IBD score of 1, first-degree rel-
atives have an IBD score of 0.5, second-degree relatives an IBD score of 0.25,
and third-degree relatives an IBD score of 0.125. IBD scores can deviate from
these values due to population structures and genotyping errors. For example,
two siblings that share same mother but two different fathers (who are broth-
ers) will have an IBD score of 0.3125 (0.25 + 0.125/2). However, an IBD score
of 0.1875 is used to remove related individuals (mean score between second-
and third-degree individuals) [45].
• SNP genotype call rate: Removing low-quality SNPs and those with a
low genotype call rate will help reduce both false positive and false negatives.
Different measures are taken here. Generally, a 95% call rate is considered the
threshold for filtering out SNPs [45].
• SNP MAF: MAF is dependant on sample size [49, 45]. SNPs with very low
MAF (≤1-5%) tend to end up as false positives. For a very large dataset, a
threshold of 1-5% is enough to ensure sufficient power to detect rare variants.
In a smaller dataset, however, it is necessary to observe at least 2030 of a given
genotype [49]. A rule of thumb is to put the MAF threshold at 10/n, where
n is the sample size. This way SNPs that pass this threshold, might have
the chance to pass the genome-wide significance level in case control studies.
For example, in a GWAS setup where we have cases and controls, if a SNP is
present only in 25 heterozygous, and all of them in cases, the P value will be
approximately 0.525 ≈ 2.98× 10−8.
• Hardy-Weinberg equilibrium (HWE): Deviation from HWE is associated
with false positives [45, 49]. Such deviation can happen when genotype call
algorithms do not assign genotypes properly. Generally, the p value threshold
for HWE is set at relaxed threshold of 10−3 or a stringent threshold of 10−6
[46, 49].
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Figure 2: Cis- and trans-eQTLs. Cis-eQTLs are eQTL within a certain distance
of transcript start (TSS) and transcription end sites (TES) (e.g. A and SNPB
within 1 Mbp ). Trans-eQTLs are more than 1 Mbp from TSS and TES, and
they can also reside on different chromosomes than their regulating genes (e.g.
SNPC).
1.3 eQTL Mapping
GGES use the power of intermediate phenotypes such as mRNA abundance as a
sensor between genome and a clinical phenotype. Genotypes are integrated with
mRNA abundance (i.e., gene expression) to link the genotypes with gene expres-
sion. In one of the first attempts [50], the global gene expression of 6215 genes
was compared against 3312 SNPs in 40 yeast segregants. Essentially, this was done
by using two matrices: a 6215 × 40 matrix for gene expression and a 3312 × 40
matrix for SNPs. In this study eQTLs were defined as cis- and trans-acting eQTLs;
Cis-acting eQTLs (cis-eQTLs) as SNPs within 10 kbp of gene boundaries and trans-
acting eQTLs (trans-eQTL) as those outside this range [Figure 2].
With increasing number of SNPs, individuals, and other quantities, there is in-
creasing need to adopt methods that provide faster and accurate results. In this
thesis, two different methods were used for eQTL mapping: kruX, and Matrix-
eQTL. The former is described in paper I, and the latter was published by Shabalin
in 2012 [51].
1.3.1 Permutations and Resampling
Permutation tests are nonparametric randomization procedures for determining sta-
tistical significance or estimating empirical false-discovery rates (FDR). These pro-
cedures are a robust approach in which data labels are shuffled multiple times. In
each shuffled set (i.e., a permuted data set), test statistics are computed. The test
statistics of permuted data sets generate a distribution under the null hypothesis.
By aggregating these test statistics and comparing with the observed one, one can
estimate the probability of obtaining a similar or an extreme effect compared to the
null hypothesis. Permutation tests are specifically useful when the null hypothesis
is no association. For eQTL mapping and estimating FDR, sample labels either in
genotype or gene expression data matrices are permuted. This approach was used
in paper I to estimate empirical FDR. For inherited risk enrichment analysis, a re-
sampling procedure was adopted to mimic the experimental data set, as explained
below and it was used in papers II and III, accordingly.
1.4 Inherited Risk Enrichment Analysis
Gene and SNP set inherited risk enrichment analyses have been gaining attention
during past years [52, 53]. These methods attempt to analyze the association of
group of functionally related genes with a disease of interest as opposed to tradi-
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tional analysis of GWAS data focusing on SNPs one-by-one. In this fashion, GGES
may compensate for potential drawbacks of GWAS that may underlie the fact that
genome-wide significant variants so far explain only a small portion of CCD heri-
tability [35]. Some of the weaker associations (i.e. P ≥ 10−8) filtered out by GWAS
because of the vast multiple testing correction may in fact be true variants affect-
ing disease. Gene and SNP set risk enrichment analysis methods instead focus on
testing prioritizing and grouping signals gathered from multiple SNPs either defined
by genes [53], pathways [54], or by selecting SNPs based on their effect on gene
regulating in the form of eQTLs [55].
1.4.1 From SNPs and Genes to eQTLs
A meaningful link between inherited genetic risk between genes or SNPs and disease
should be established. This is crucial to be able to explain the proportion of inherited
risk that is not explained by GWAS. Thus, in using GWAS results, an important
step to analyze SNPs or genes for inherited risk for a disease is to make a link
between the experimental set of genes to SNPs in GWAS. If the starting set is a
list of SNPs, this can be achieved using GGES and eQTLs. Basically, eQTLs for
each SNPs will be selected either through a direct hit or using LD. r2 which is the
correlation between two SNPs and reflects the LD strength can used. The cutoff
for r2 can be the same as the cutoff used to identify so-called tag SNPs in HapMap
[29, 28]. This step, to select and expand SNPs using eQTL datasets, is referred to as
“LD expansion”. The starting set can also be a list of genes. This list can come from
different sources, including computational approaches such as clustering approaches,
or gene interaction network analysis, or it can come from annotated sources such as
The Kyoto Encyclopedia of Genes and Genomes [56], Gene Ontology (GO) [57, 58],
or REACTOME [59].
SNPs can be assigned to genes in various ways. It can be done through the
proximity of an SNP to a gene or through a functional or statistical association with
the gene. For distance, different measures have been used, including 5 kb [60], 20
kb [61], 50 kb [62], 200 kb [63], and 500 kb [64]. Although SNPs that influence gene
expression have been found as close as 20 kb from a gene [65], these types of selection
for SNPs might also pick up those that are in no way associated with the gene. To
overcome this problem, eQTLs from GGES studies is useful. eQTLs will provide a
true link between a SNP- gene pair. A practical issue with eQTLs is that not all of
the relevant SNPs will be selected. One way to solve this is to use the LD-expansion
technique described above. This way, those SNPs that were not picked up by eQTL
studies will be covered as well.
1.4.2 From eQTLs to GWAS
The next step would be to identify how the LD-expanded set overlaps with the
millions of SNPs identified through GWAS. This can be done by accessing GWAS
summary results and capturing the disease association P value for SNPs in the LD-
expanded set. Since some genes might be close to each other, the identified SNPs
(through eQTLs) might be redundant. This can be a potential source of bias due to
LD between SNPs [64, 66]. The effect of LD bias should be mitigated as much as
possible to prevent inflation or deflation of signals. This can be done by LD pruning
techniques to reduce the number of redundant SNPs. This set is called LD-pruned
set of SNPs.
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Figure 3: Schematic of inherited risk enrichment analysis. This schematic illus-
trates an overview of inherited risk enrichment analysis. Starting from a set of
genes to finally assign an enrichment score to the gene set.
1.4.3 Statistical Significance Assessment
To assess statistical significance, a resampling technique can be used. If the starting
set is enriched with disease causing SNPs or genes, the resulting set (after pruning)
should also be enriched in disease risk. To test this, an enrichment score can be
defined as the ratio of disease-causing SNPs to non-disease-causing SNPs compared
to the background data, which is millions of SNPs in the GWAS summary results.
The SNPs in a GWAS panel, however, do not reflect the smaller set of SNPs in
the LD-pruned set of SNPs. Millions of SNPs in GWAS panel represent the whole
genome, but the SNPs in the LD-pruned set might be distributed only in parts of
genome or even aggregate on a single chromosome. So a null distribution must be
constructed to mimic the LD-pruned set as much as possible. A couple of factors
should be considered. First, we must consider the chromosomal distribution of SNPs.
A background data set should have the same number of SNPs in each chromosome
as the LD-pruned set. Second, we must consider MAF distribution. Again, it is
important to construct background data based on the MAF distribution of LD-
pruned set. To do so, SNPs in the LD-pruned set are binned into 5 groups. These 5
groups are starting from 0 with steps of 0.1. Third, we must select those SNPs based
on the criteria for the LD-expanded set. That is, if SNPs were selected based on
cis-eQTLs that are within 1 Mbp of the gene window, the background data should
only include those SNPs from GWAS summary result that are within 1 Mbp of a
gene. Last but not least, the number of SNPs in the background data should match
number of SNPs in the LD-pruned set. This procedure should be repeated a couple
of thousand times to approximate a null distribution. All the procedures above
are proposed as an algorithmic framework under the term inherited risk enrichment
analysis as described in Figure 3 and Algorithms 1 and 2.
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Algorithm 1 Stage one: Assign Freal to the list of input genes
Input: A list of genes
Output: Freal
1. Map eQTLs for each gene in the gene set from GGES dataset
2. Expand eQTLs using LD
3. Prune the expanded eQTL list
4. Record disease association P values for each SNP in the pruned set from
GWAS dataset
5. Nreal ← SNPs with P value ≤ 0.05
6. Ntot ← Total number of SNPs with a disease association P value
7. Freal ← NrealNtot
Algorithm 2 Stage two: Resampling procedure to construct a null distribution for
Fscr
Input: List of LD pruned SNPs from stage one
Output: Frand
1. If using cis-eQTLs, select only SNPs within 1Mb of TSS of genes from
GWAS summary results
2. Permute SNP index IDs in GWAS summary results
3. For n=1,...,10000 select Ntot SNPs by:
(a) Matching chromosomal distribution of LD pruned eQTLs
(b) Matching MAF distribution of SNPs (five MAF bins
[0, 0.1), ..., [0.4, 0.5])
(c) Nnrand ← SNPs with P value ≤ 0.05
(d) Fnrand ←
Nnreal
Ntot
4. Fscr ← Freal〈Frand〉
5. Calculate P value P (Z ≤ z):
z = Nreal−N¯rand√
1
1−n
∑n
i=1 |N irand−N¯rand
2|
, n = 10000
X
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2 Aims
The overall aim of this thesis is to develop a reliable method for eQTL mapping
from genetics of gene expression studies using the STockholm Atherosclerosis Gene
Expression (STAGE) study of coronary artery disease (CAD) patients allowing to a
build a computational pipeline for inherited risk enrichment analysis of eQTLs by re-
examining datasets of genome-wide association studies (GWAS). New and existing
methods were used to develop these methods to assess the heritability (and thereby
causality) of eQTLs and associated genes active in molecular processes (in up to
regulatory gene networks) identified in specific and multiple tissues important for
primarily CAD.
2.1 Specific Aims
The specific aims of the individual papers are:
Paper I: To develop a fast nonparametric eQTL mapping method.
Paper II: To develop a method for inherited risk enrichment analysis based on
eQTLs and GWAS datasets and to use this method to investigate the inherited
risk enrichments of eQTL sets identified in seven CAD-relevant tissues of the
STAGE study.
Paper III: To apply the method of inherited risk enrichment analysis to multi-tissue
regulatory gene networks identified in STAGE.
Paper IV: To use the STAGE and Athero Express studies to map eQTLs of three
atherosclerosis candidate genes (ALOX5, ALOX5AP, and LTA4H) and their
associations with phenotypes in Athero Express.
X
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3 Present Investigations
3.1 Paper I: kruX an eQTL Mapping Tool
mRNA abundance is one of the most proximal sensors of DNA variation. It reflects
the interactions between the genotype and microenvironment within a tissue [43, 44].
This interaction can be captured at any stages of the disease. eQTL mapping tools
can be used to analyze combinations of hundred thousands of SNPs and tens of
thousands of genes (or any qualitative trait) all at once. In this paper, we developed
a bioinformatic tool for fast eQTL mapping. We named it kruX, which is based
on the Kruskal-Wallis test statistics. In summary, kruX excels in detecting higher
proportion of non-linear associations than other methods. This tool was developed
for Python, MATLAB, and R, and it is available online.
3.1.1 Matrix Multiplications for Fast Calculations
kruX has two input matrices: genotype (G) and gene expression (D). G is organized
as M genotype marker by K individuals; D is organized as N transcripts by K
individuals. In kruX, genotype markers have the values 0, 1, or 2 (i.e., AA, Aa, and
aa). This method assumes that the data has passed necessary QC filters. kruX will
convert matrix G into a sparse logical matrix, and rank gene expression matrix D
into a rank matrix of R. Then the Kruskal-Wallis test statistics matrix S will be
calculated through matrix multiplications. For P value calculations, a nominal P
value threshold of Pc is chosen by the user. Corresponding test statistics threshold
for Pc is then calculated for 1 degree of freedom. kruX then will remove those that
exceed test statistics threshold from matrix S. P values for the rest of the values
are then calculated using χ2 distribution. Empirical FDR values are estimated by
permuting columns on the expression data ranks. The FDR value for is then defined
as ratio of average number of associations in the permuted data to the number of
associations in the original data. kruX comes with an example data and script
from 2000 randomly selected genes and markers from 100 randomly selected yeast
segregates [67].
3.1.2 kruX is Fast and Accurate
kruX was validated by testing each and every association one by one using built-
in Kruskal-Wallis functions. We then analyzed kruX for 19,610 gene expression
profiles and 530,222 SNPs from the STAGE dataset [68]. kruX relies on matrix
multiplication to calculate test statistics and was at least 11,000 times faster than
running a Kruskal-Wallis test for each SNP-gene association test. We compared the
results from kruX to the results from the popular Matrix-eQTL method [51]. Matrix-
eQTL has two parametric ANOVA and linear model options. Since the Kruskall-
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Figure 4: Relative proportion of identified eQTLs and their types. Identified
eQTLs are divided into three groups: common eQTLs (white), skewed genotype
group (yellow), and nonlinear eQTLs (red). Each bar represents one group of
eQTLs. Common refers to the eQTLs found by all three models. kruX has the
highest relative proportion of identified nonlinear associations, while linear and
ANOVA models are second and third, respectively
Wallis test is more conservative than ANOVA and linear models, the nominal P
values will be higher. Thus it is not possible to compare P values directly. To be
able to compare them, we performed empirical FDR correction for multiple testing
and filtered out identified eQTLs at various FDR cutoffs. Most of the identified
eQTLs didnt pass the FDR filter when we used the ANOVA model in Matrix-
eQTL. The sheer numbers of eQTLs identified with kruX and with the linear model
in Matrix-eQTL, however, were more or less comparable. We found that this is due
to pairs of rare homozygous minor alleles and gene expression outliers. However, the
results were more or less comparable when considering cis-eQTLs only. ANOVA in
Matrix-eQTL also proved to be sensitive to gene expression outliers and SNPs with
rare homozygous alleles. The linear model showed the highest number of associations
after FDR correction, owing to the additive linear associations. The eQTLs identified
with all three approach are summarized and compared in Figure 4.
3.2 Paper II A Multitissue Repository of eQTLs for
CAD
GWAS have identified at least 150 loci for CAD and MI [69]. Of these 150, 46 were
found through GWAS meta-analysis [70, 71, 72]. These loci are believed to con-
tribute to at least 10% of inherited risk [72]. SNPs that do not reach a genome-wide
significance level after P value correction (≥ 10−8) and rare SNPs might contribute
to the missing 90% of heritability [43, 73]. Since CAD is a complex systemic disease,
disease-causing variants and SNPs might exert their risk for CAD across multiple
tissues [8, 74]. In this paper, genome-wide genotype and global gene expression
data from the multi-tissue STAGE study were used to identify eQTLs in and across
seven CAD-relevant tissues [68]. In summary, we identified 16 multi-tissue eQTLs
associated with 19 master regulatory genes. Three of the 19 master regulatory
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Figure 5: Inherited risk enrichment analysis results for cis-eQTLs in STAGE.
(A) CAD/MI risk enrichment for tissue-specific eQTLs. (B) CAD/MI risk en-
richment for tissue shared eQTLs. (C) CAD/MI risk enrichment for cis-eQTLs
in found in 2 to 7 tissues. (D) Pie chart showing risk enrichment for eQTLs
in tissue combinations. Each pie represents one tissue. Each layer for each
pie shows the enrichment of tissue shared eQTLs and a combination of 1 to 5
tissues. For each section in each pie, the highest risk enrichment score for the
possible combinations of the said tissue with other tissues is indicated.
genes segregated the patients according to the extent of CAD. Furthermore, siRNA
targeting of these genes in the THP-1 monocytic cell line also incubated with acety-
lated LDL affected cholesterol-ester accumulation in this in vitro model of foam cell
formation [75].
3.2.1 Integrating GGES and GWAS
Samples of seven CAD-relevant tissues - atherosclerotic arterial wall (AAW), in-
ternal mammary artery (IMA), subcutaneous fat (SF), visceral fat (VF), skeletal
muscle (SM), liver, and whole blood (WB) - were obtained from STAGE patients
for RNA extraction. Whole-blood samples were also obtained for RNA and DNA
extraction. DNA from 109 patients was genotyped with GenomeWideQTL 6 arrays
(Affymetrix). Custom-made HuRSTA-2a520709 arrays (Affymetrix) were used for
gene expression profiling of the RNA samples. kruX was used to survey 19,610 iden-
tified mRNA expression traits for association with each of the genotyped SNPs at
FDR 15%. cis-eQTLs were defined within 1Mb of transcription start or end site,
and the rest of eQTLs as trans-acting eQTLs. The cis-eQTL with lower P value
for each gene in each tissue was used for the inherited risk enrichment analysis.
The cis-eQTLs were LD-expanded with SNP at r2 threshold of 0.8 according to the
European population panel in 1000 Genomes project data [76]. Next, the summary
statistics of GWAS datasets from two independent studies and one meta-analysis
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Table 1: Cis-eQTLs identified in seven different tissues and their corresponding
number of genes and P value cutoff
Tissue No. of
eQTLs
No. of Genes
No. of Gene-
eQTL Pairs
P value cutoff
AAW
3579 799 3716 2.5× 10−4
IMA
4979 1122 5304 2.9× 10−4
SF
3867 876 4024 3.0× 10−4
VF
4012 923 4324 2.4× 10−4
SM
5046 1095 5315 3.0× 10−4
Liver
10180 2158 10927 4.0× 10−4
WB
15012 2984 16952 6.7× 10−4
Total cis-eQTL
29530 6450 34611 N/A
Total shared
cis-eQTL
7429 1839 6986 N/A
Total tissue
specific cis-eQTL
22101 4611 27625 N/A
were used to assign the expanded cis-eQTL group with P values indicating associ-
ations with CAD. For this we used two independent GWAS: the Wellcome Trust
Case Control Consortium (WTCCC) [46] and the Myocardial Infarction Genetics
Consortium (MIGen) [77] studies. For replication and validation of results, we used
Coronary Artery Disease Genome-wide Replication and Meta-analysis (CARDIo-
GRAM) [71, 72]
Next, sets of genes co-expressed with genes regulated by cis-eQTLs in the same
tissue were identified at a Pearson correlation coefficient threshold ≥ 0.85. These
gene sets were then characterized using Gene Ontology (Fisher’s exact test). Ben-
jamini and Hochberg FDR corrections were used to correct for multiple testing.
3.2.2 Patterns of Carrying Disease Risk for CAD in Groups of
eQTLs
We identified 29,530 cis-eQTLs for 6,450 unique genes by analyzing 19,610 genes
across 7 tissues (Table 4). 25% of all the identified cis-eQTLs (7,490) were found
in at least two other tissues. When investigating individual tissues, at least 60%
of cis-eQTLs in each tissue were also found in another tissue. These eQTLs were
referred to as tissue-shared eQTLs. The total number of identified trans-eQTLs
was 1,494, and 2.9% of them were found in at least two tissues. Similar propor-
tions for cis- and trans-eQTLs were previously reported [78, 79, 80, 81]. In general,
tissue-shared eQTLs were found to be closer to transcription start and end sites
than tissue-specific eQTLs.
The entire set of cis-eQTLs was enriched in CAD risk by 1.15-fold in the MIGen
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GWAS data set [77] and by 1.2-fold in the WTCCC data set [46]. In general, tissue-
shared eQTLs in each tissue were more enriched in CAD risk than tissue-specific
eQTLs [Figure 5A and 5B]. We found that eQTLs shared among 4, 5, or 6 tissues
were more enriched than those shared among 2, 3, or 7 tissues [Figure 5C]. Inves-
tigating this further, tissue-shared eQTLs in specific combination of tissues showed
a similar trend. In other words, we ran inherited risk enrichment analysis for all of
the 120 possible combinations of tissues. The inherited risk enrichment of eQTLs
peaked at combination of 5+ tissues in both GWAS datasets [Figure 5D]. Taking
the eQTLs identified across at least 4 tissues, we found 42 multi-tissue eQTLs in
two sets of 5 (AAW, liver, SF, VF, and WB) and 6 (IMA, liver, SM, SF, VF, and
WB) tissue combinations to be highly enriched. The enrichment for these two sets
were replicated in CARDIoGRAM, a GWAS meta-analysis for CAD [71, 72].
We analyzed the above two sets by assessing the downstream effects of gene
expression governed by identified 42 eQTLs. We found 29 gene sets for 16 of the
42 eQTLs. These 16 eQTLs were referred to as master regulator eQTLs. Nineteen
unique cis-regulated genes (of 29 gene-sets) were also identified. These genes are
referred to as master regulator genes. The identified 16 master regulatory eQTL
set was enriched even further than the starting set of 42 eQTLs according to the
CARDIoGRAM GWAS dataset. We assessed the functional characteristics of the
29 gene sets using Gene Ontology [58]. 19 gene sets had a significant P value for
CAD-relevant categories. These gene sets were also associated with CAD pheno-
types in STAGE. Four of the master regulatory genes were associated with both
functional and biological processes and with the degree of CAD in STAGE. The
disease association of these genes was further validated in a THP-1 foam cell model
by siRNA targeting. siRNA inhibition of three of the four (G3BP1, FLYWCH1, and
PSORS1C3) master regulators markedly reduced cholesteryl-ester accumulation in
a THP-1 foam cell model.
3.3 Paper III: A Cross-tissue Analysis of Regulatory
Gene Networks
Molecular networks are crucial for understanding how genetic and environmental
factors interact to affect CCD development and progress. To achieve a clear under-
standing of molecular and regulatory gene landscape, an integrative systems genetic
approach was proposed [38, 82, 43]. This is done by identifying co-expression mod-
ules, inferring regulatory gene networks (RGNs) and by identifying key drivers in
these RGNs. In this paper, a multi-tissue cross-species systems genetic approach
was taken to identify and study RGNs and their role in CAD. First, co-expression
modules were identified by weighted gene co-expression network analysis (WGCNA)
across seven tissues. Then, to investigate the CAD causality for these modules, we
used the CARDIoGRAM datasets for the inherited risk enrichment analysis. RGNs
were inferred by Bayesian framework and key driver analysis. The cross-species
conservation of the identified RGNs was investigated using the Hybrid Mouse Di-
versity Panel (HDMP) [83]. Finally, key drivers in cross-species validated RGNs
were further targeted with siRNA in the THP-1 foam cell model.
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3.3.1 Identifying Cross-tissue Co-expression Modules Associated
with CAD
Co-expression modules were identified across tissues using the WGCNA method
[84]. Resulting modules were then associated with four main CAD phenotypes as
Figure 6: Schematics of analytical steps starting with the STAGE study. (A)
Sampling tissues in STAGE study for mRNA profiling. (B) Multi-tissue
WGCNA method for constructing tissue-specific and cross-tissue modules. (C)
Detecting co-expression module associations with 4 main CAD phenotypes as-
sessed in the STAGE study. (D) Analyzing causality of modules using STAGE
eQTLs and GWAS using inherited risk enrichment and GSEA-like analyese. (E)
Reconstruction of RGNs by using Bayesian framework and key driver analysis.
(F) Using the HMDP dataset for cross-species validation of RGNs. (G) siRNA
targeting of key drivers in the foam cell in vitro model.
described [85]: (1) extent of coronary atherosclerosis, (2) plasma levels of total
cholesterol, LDL, VLDL, or HDL, (3) plasma glucose, HbA1c, insulin, or proinsulin
levels, and (4) C-reactive protein levels which is an inflammatory marker. Next,
CAD causality of phenotype-associated modules was examined by the inherited risk
enrichment analysis using a total of six GWAS datasets: (1) CAD [71, 72], (2)
fasting glucose [86], (3) HbA1c [87], (4) fasting proinsulin [88], (5) blood lipids
[89], and (6) type 2 diabetes [46]. For modules without sufficient number of cis-
eQTLs (n < 10), we instead used SNPs located in the vicinity of each module gene
(+/-500kb of TSS) and adopted a new gene set enrichment analysis (GSEA)like
method [53]. CAD association P values for each eQTL/SNP/module were assigned
based on the corresponding SNP P value in GWAS. A competitive null hypothesis
was created from equally sized random sets of genes (n=1000) to enable comparing
degree of CAD association in the STAGE-phenotype associated modules to the null
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distribution. The pipeline is summarized in Figure 6.
3.3.2 A Cross-tissue Cross-species Validation of Regulatory Gene
Networks for CAD Causality
The WGCNA revealed 171 modules; 94 were tissue specific, and 77 were cross-
tissue modules. Of the 171 modules, 61 were associated with at least one of the
four main CAD phenotypes in the STAGE patients. By analyzing these modules
for inherited risk enrichment, GSEA-like score, and GWAS genes, we identified 30
CAD-casual modules. For example, we found eight RGNs that were related to the
extent of coronary atherosclerosis (assessed in pre-operative angiograms). Two of
these eight RGNs found in SF had 10 and 15 CAD candidate genes identified by
GWAS, respectively. Three of these 8 RGNs were found in AAW and enriched
in various functional processes of high relevance for atherosclerosis (e.g., immune
system processes, HDL cholesterol levels, and RNA-processing genes). These three
RGNs were also and highly enriched in CAD association according to risk-enrichment
analysis.
In cross-species analysis, mouse orthologs to genes in 12 of the 30 CAD-causal
modules were also associated with corresponding mouse phenotypes in the HMDP
study [83]. Three of these cross-species validated CAD-casual modules (RGNs 42, 58,
and 98) were associated with the extent of both human and mouse atherosclerosis.
Key drivers in these three RGNs were targeted in the THP1 foam cell model using
siRNA where key drivers in RGN 42 was found to affect foam cell formation in
vitro.
3.4 Paper IV: DNA Variants in Three Eicosanoid path-
way genes
Three genes (ALOX5, ALOX5AP, and LTA4H) in eicosanoid pathway are believed
to be involved in atherosclerosis and CAD. Expression of these genes is elevated
in atherosclerotic plaques (both in human and mice) [90, 91] , and SNPs in these
genes are associated with carotid intima-media thickness [92], myocardial infarction,
CAD, and ischemic stroke [93, 94, 95]. Despite their involvement in CAD/MI, no
significant variants have been reported in these genes by GWAS . In this paper,
SNPs in these three genes were extensively studied using two independent datasets:
STAGE [68] and the Athero-Express Biobank Study (AE) [96]. Genotype imputation
and cis-eQTL analysis methods (such as kruX) were used to analyze the SNP-gene
associations. In sum, we found only one significant eQTL, in LTA4H in WB in
the STAGE study. No significant eQTLs in these genes were identified in the AE
dataset.
3.4.1 Identifying DNA variants in ALOX5, ALOX5AP, and LTA4H
STAGE and AE genotypes were imputed by using 1000 Genomes EUR population
panel, and SHAPEIT2 [97, 98] and IMPUTE2 [97] softwares. In STAGE, kruX
method was used for cis-eQTL inference as descibed. SNPs within +/- 50kb of
the three genes with at least 97% call rate or imputation quality of ¿ 0.9 were
investigated.
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3.4.2 There is no Association between DNA Variants and Three
Eicosanoid Gene Expression
1,454 SNPs in AE and 1,078 SNPs in STAGE were examined. Consecutively, all
the associations were corrected for multiple testing: for the plaque phenotypes: p
= 0.05/(7 histological phenotypes × 1453 independent variants) = 4.92 × 106, for
serum protein level association with SNP: p = 0.05/(2 serum proteins × 1453 inde-
pendent variants) = 1.72×105 ; and finally for eQTL analysis: p = 0.05/(3 genes ×
7 tissue types × 1078 independent variants) = 2.21× 106 pvalue cutoffs were used.
In STAGE, only one eQTL (rs6538697) associated with LT4AH expression in WB
passed the multiple testing correction.
In AE, two SNPs, rs4627178 for ALOX5AP and rs752059 for ALOX5, were asso-
ciated with serum protein levels. Furthermore, rs9743326 was found associated with
intraplaque microvessels, and rs17216508 with the number of smooth muscle cells
in the atherosclerotic plaque as assessed in AE. However, none of these associations
remained significant after correction for multiple testing.
X
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4 Discussion
DNA variations identified by GWAS explain only a small proportion of the risk
for CCDs [38, 43]. The possible reasons were discussed in Introduction (interac-
tions between environmental and genetic factors, rare DNA variants, etc). New
approaches, such as GGES, seek to utilize mRNA abundance as a sensor for DNA
variation and thereby better understand how genetic variance affects clinical pheno-
types as RNA abundance reflects the combined effects of DNA variation and tissue
microenvironments. One of the core goals of GGES is to identify genome-wide
eQTLs, which computationally is not an entirely trivial task. This is because there
are approximately 8 million SNPs at the 5% MAF cutoff [99], and approximately
20,000 protein-coding genes. If all possible associations are tested (i.e., all possible
SNP-gene associations), 160× 1012 individual tests needed. One way to reduce the
computational burden is to use matrix multiplications. This is the basis for eQTL
mapping techniques, such as Matrix-eQTL [51], to accelerate testing of billions of
associations. The software tool developed in Paper I, kruX, aimed to address some
shortcomings of Matrix-eQTL in detecting nonlinear associations (due to skewed
genotype groups) and to find a method to reduce the sensitivity to data outliers.
kruX is based on a nonparametric statistical test, Kruskal-Wallis, and uses matrix
multiplications to speed up the computations. We found that the Kruskal-Wallis
test used in kruX is more conservative and less sensitive to data outliers than the
two models (ANOVA and additive linear models) used in Matrix-eQTL.
In paper II, we used kruX to identify eQTLs in the STAGE dataset (consisting
of seven CAD metabolic and vascular tissues) and inherited risk enrichment anal-
ysis to examine CAD-associated risk. We discovered that shared-tissue cis-eQTLs
(those present in more than one tissue) were generally more enriched in CAD risk
than tissue-specific eQTLs. This effect was even more pronounced for eQTLs ac-
tive across many tissues (i.e., > 4 tissues). This suggests that there is a complex
interaction of genetic regulation of genes in CAD between metabolic and vascular
tissues. We investigated the possibility that this higher enrichment for eQTLs found
in multiple tissues is not a result of stronger association with the expression traits for
multi-tissue eQTLs than tissue-specific. In testing this, we found that eQTLs with
high P values were not further enriched than eQTLs with low P values regardless of
the eQTLs were tissue-shared or tissue-specific. Moreover, there were no significant
correlations between eQTL P values (tested at FDRs 10%, 15%, and 20% and MAF
of 0.05, 0.10, and 0.15), and GWAS P values. In sum, these results strongly support
the notion that eQTLs active across multiple vascular and metabolic tissues are of
stronger relevance for CAD risk and etiology than tissue-specific eQTLs.
A comprehensive method, gene set enrichment analysis (GSEA), was proposed in
2005 to analytically score gene sets of interest based on common biological functions
[53]. Since then, numerous methods and applications for such analysis were devel-
oped. SNP-based set enrichment analysis (SSEA), built on GSEA, was developed
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to study SNP sets instead of genes [52]. SSEA uses SNP information from GWAS
to study enrichment of gene sets. In SNP-based approaches, SNPs for each gene are
identified (e.g., distance to gene), a single P value for each gene is assigned, and
finally a score for gene sets is assigned through empirical permutation techniques or
statistical tests.
The possible problem with GSEA and SSEA techniques surfaces when SNPs are
chosen solely on the basis of their physical distance from their gene. This distance
can range from 5 kb to 500 kb in different publications. Inherited risk enrichment
analysis uses positive features of SSEA and GSEA and integrates them into a sin-
gle pipeline. In contrast to GSEA-like methods, inherited risk enrichment analysis
uses eQTL information to assign SNPs to genes. eQTL-gene association is a more
reasonable choice than assigning SNPs to gene based on a mere distance. Another
issue with GSEA-based methods is gene set size. It is a potential source of bias,
as the number of genes increases in a gene set, the possibility of higher risk scores
increases. Some of the new approaches to GSEA try to correct for gene set size. In
the inherited risk enrichment analysis pipeline that we developed, only eQTLs are
taken into account, and any potential effect from gene set size is mitigated through
permutations and pruning steps. Indeed, in Paper II, we show that gene sets with a
large number of genes were generally not more enriched than gene sets with a small
number of genes.
With GSEA and GSEA-like methods, depending on the gene length and gene
set size, SNPs that are assigned to each gene might be redundant. For example,
if genes are closer and the search windows are overlapping, same signal (i.e., SNP
P value) from overlapping regions will be selected multiple times. Thus, inflation
of results due to redundant SNPs can be an issue. Our inherited risk enrichment
analysis operates only at the SNP level, and mitigates the redundant SNPs issue by
LD pruning after eQTL expansion. (SSEA implements an LD-pruning step, but it
still doesnt consider overlapping genes.) Our approach also removes any potential
bias from gene length and inflation or deflation of results due to LD between SNPs
and their statistical significance in GWAS.
The inherited risk enrichment analysis method also includes permutation and re-
sampling approaches. These approaches can be implemented at three levels: genes,
individuals, and SNPs. At the gene level, indexes of genes are randomized and re-
sampled. This is suitable only when analyzing gene sets at the gene level, and it
doesnt consider SNP distribution nor LD structures between SNPs. At the individ-
ual level, permutation is computationally intensive and requires access to individual
level data. In this approach, indexes for the individuals are permuted and test statis-
tics for each SNP are re-calculated, then for each gene set a new test statistics is
assigned. Since individual level data is not always accessible and is computationally
intensive it is rarely used. The SNP level approach, however, is more similar to gene
level permutation. Either SNP indexes are permuted or they are resampled based
on certain criteria. It is easier to maintain LD structure between SNPs, MAF, and
chromosomal distribution of the SNPs, and number of the SNPs when permuting or
resampling at the SNP level. In our inherited risk enrichment analysis, we therefore
used resampling at the SNP index level.
A possible drawback of inherited risk enrichment analysis is its reliance on eQTL
information from the STAGE study. Almost two thirds of genes in STAGE dataset
didnt have any eQTLs. Thus, if there are fewer than about 10 eQTLs/gene set,
this method is not useful. The lack of sufficient number of eQTLs/SNPs to analyze
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gene sets is, however, also a challenge for GSEA and SSEA methods. A larger eQTL
datasets become available the problem with lacking eQTLs for genes will be reduced.
In sum, the inherited risk enrichment analysis provides a powerful tool integrat-
ing GGES and GWAS to assign disease relevance to lists of genes as judging from
their combined association with disease. In this thesis we used the STAGE GGES
and GWAS to implement this strategy for CAD. However, as GGES will be per-
formed on other complex traits and CCDs, this new data-driven unbiased approach
of extracting disease relevance for lists of genes/transcripts (e.g., defined by differ-
ential expression on up to gene networks), we think, has the potential to grow in
importance and utility. Inherited risk enrichment analysis (and similar methods
that use eQTL data) is also a powerful approach to study disease causality. In
paper III, gene modules were considered causal if any of the genes in the module
were known CAD candidate genes for genome-wide loci identified by GWAS or if
the module eQTLs were enriched in CAD risk according to our inherited risk en-
richment analysis reusing GWAS datasets. The notion that disease association also
refers causality is principally based on the central dogma in biology. In brief, the
central dogma states that genetic variation always is upstream of (e.g. causal for)
gene expression that in turn is upstream of variation in the phenotype (e.g., disease).
As a consequence, SNPs are always causal for gene expression and from that it can
be inferred that genes with eQTLs are more likely to also to affect the disease (i.e.,
to be causal) and not to be regulated by disease (i.e., reactive). Adding the GWAS
disease information, we can further refine this logic to specifically seek causality for
different diseases (e.g., CAD) or phenotypes (e.g. LDL levels).
In Papers II and III, the combination of the STAGE study and inherited risk
enrichment analysis was used to identify new CAD target genes and gene networks.
The unique multi-tissue STAGE dataset can also be used to further validate the
importance of more established atherosclerosis and CAD candidate genes. This was
one of the main goals in Paper IV. Specifically, the STAGE dataset was used to
study three previously known genes (ALOX5, ALOX5AP, and LTA4H) involved in
the inflammation-mediating eicosanoid pathway associated with atherosclerosis de-
velopment. By analyzing the effect of common variants on gene expression (i.e.,
eQTLs), circulating protein levels, and several atherosclerotic plaque phenotypes,
we found only one significant association between these parameters in the form of a
eQTL in whole blood for LTA4H. These results are in line with GWAS of CAD/MI
[71] where these genes have not been reported. Thus, paper IV is a first indication
that eQTL mapping and consequently using these eQTLs in integrative analysis re-
using GWAS datasets in the form of inherited risk enrichment analysis, is not only
a data-driven (i.e., unbiased) approach to identify novel candidate genes and gene
networks underlying complex traits like CAD but also tools to re-assess the impor-
tance of established disease risk genes. Importantly, however, the fact that a gene is
not genetically regulated (e.g., have eQTLs) that also are associated with a complex
trait according to GWAS, does not rule out a causative role in disease/phenotype
development. In fact, we generally observe that key drivers of gene networks asso-
ciated with CAD (Paper III) are not in themselves regulated by eQTLs associated
with CAD. A plausible explanation for this observation might be negative selection
of genetic variants affecting key regulatory genes through evolution as such variation
may not be in agreement with successful breeding (e.g. cause embryonic or early life
lethality).
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5 Concluding Remarks
In this thesis, we have integrated the unique GGES STAGE with GWAS using a
system biological approach [100] to increase our understanding of CAD. We think
this approach is powerful as it does not consider single gene associations with CCDs,
which risk rendering spurious correlations, but instead utilizes data-driven, whole-
genome and functional approaches that are needed for a better global understanding
of the complex inheritance and etiology of CCDs. Specifically, we think the eQTL
mapping technique; kruX and the inherited risk enrichment analysis methods pro-
posed in this thesis should be useful to improve our understanding of other CCDs
besides CAD.
In the future, similarly as we historically have been integrating single DNA vari-
ants, genes, proteins and/or metabolites with disease phenotypes, we foresee that
CCD understanding will be faster advanced by also integrating these features a the
genomic, transcriptomic, proteomic, metabolomic levels with phenotypic/clinical
data. To do so we do not only need more cost-effective and reliable screening meth-
ods (e.g., RNA sequencing) but also better and more robust computational tools to
analyze and integrate these huge datasets. In the end, as in the case of individual
genes, functional gene sets, as gene networks with key drivers, need further valida-
tion both by using in silico experiments to model the dynamics of the interaction
between components in these networks and in the end, by using efficient means of
in vitro and in vivo validation experiments.
The four studies presented in this thesis each cover some aspects of systems bi-
ological steps needed to better understand CCD inheritance and etiology. However,
they are also limited to the use of eQTL datasets alone. Thus, falls short when it
comes to analyzing other modes of risk inheritance such as epigenetics and non-RNA
intermediate phenotypes such as protein abundance and metabolites. As the final
aim needs to analyze and map the entire variation and sources of risk inheritance
and disease etiology, epigenetics and non-RNA intermediate phenotypes need also
to be considered. Emerging improvements in high-throughput techniques to analyze
protein abundance [101, 102] and advances in epigenetics [103, 104, 105] will pave
the way for also integrate these sources of variance in systems biological approaches
to CCDs.
X
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